About EnteroMedics (ETRM)
EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company's initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company's VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: Health Care Equipment
- Exchange: NASDAQ
- Symbol: ETRM
- CUSIP: 29365M20
- Previous Close: $5.84
- 50 Day Moving Average: $6.70
- 200 Day Moving Average: $3.16
- 52-Week Range: $1.75 - $86.80
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.05
- P/E Growth: 0.00
- Market Cap: $40.14M
- Outstanding Shares: 6,873,000
- Beta: 2.21
- Net Margins: -3,236.52%
- Return on Equity: -1,361.34%
- Return on Assets: -190.05%
- Debt-to-Equity Ratio: 1.07%
- Current Ratio: 1.20%
- Quick Ratio: 0.93%
Companies Related to EnteroMedics:
Earnings History for EnteroMedics (NASDAQ:ETRM)Earnings History by Quarter for EnteroMedics (NASDAQ:ETRM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/3/2017|| || || || || || || || |
|5/1/2013||Q1 2013||($0.13)||($0.14)||$0.10 million||View||N/A|
|2/13/2013||Q4 2012||($0.14)||($0.17)||$0.36 million||View||N/A|
Earnings Estimates for EnteroMedics (NASDAQ:ETRM)
Current Year EPS Consensus Estimate: $-170.10 EPS
Next Year EPS Consensus Estimate: $-126.00 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for EnteroMedics (NASDAQ:ETRM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for EnteroMedics (NASDAQ:ETRM)
Insider Ownership Percentage: 1.40%Insider Trades by Quarter for EnteroMedics (NASDAQ:ETRM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/3/2016||Peter M Delange||SVP||Buy||20,000||$0.55||$11,000.00|| |
|8/13/2015||Mark B Knudson||CEO||Buy||303,000||$0.25||$75,750.00|| |
|6/19/2014||Cathy Friedman||Director||Buy||11,800||$1.70||$20,060.00|| |
|1/8/2014||Luke Evnin||Director||Sell||556,585||$2.50||$1,391,462.50|| |
|2/27/2013||Anthony P Jansz||Director||Buy||150,000||$0.95||$142,500.00|| |
Headline Trends for EnteroMedics (NASDAQ:ETRM)
Latest Headlines for EnteroMedics (NASDAQ:ETRM)
Frequently Asked Questions for EnteroMedics (NASDAQ:ETRM)
What is EnteroMedics' stock symbol?
EnteroMedics trades on the NASDAQ under the ticker symbol "ETRM."
When did EnteroMedics' stock split? How did EnteroMedics' stock split work?
EnteroMedics shares reverse split on the morning of Friday, January 8th 2016. The 1-15 reverse split was announced on Wednesday, December 23rd 2015. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 7th 2016. An investor that had 100 shares of EnteroMedics stock prior to the reverse split would have 7 shares after the split.
How were EnteroMedics' earnings last quarter?
EnteroMedics Inc (NASDAQ:ETRM) announced its earnings results on Thursday, August, 4th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.75) by $0.26. EnteroMedics had a negative net margin of 3,236.52% and a negative return on equity of 1,361.34%.
When will EnteroMedics make its next earnings announcement?
EnteroMedics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.
Where is EnteroMedics' stock going? Where will EnteroMedics' stock price be in 2017?
1 brokerages have issued 1 year target prices for EnteroMedics' stock. Their forecasts range from $3.00 to $11.06. On average, they expect EnteroMedics' share price to reach $7.03 in the next year.
Are investors shorting EnteroMedics?
EnteroMedics saw a increase in short interest in February. As of February 15th, there was short interest totalling 1,229,647 shares, an increase of 71.2% from the January 31st total of 718,396 shares. Based on an average daily volume of 3,008,913 shares, the days-to-cover ratio is currently 0.4 days. Currently, 29.0% of the company's stock are sold short.
Who owns EnteroMedics stock?
EnteroMedics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (10.07%) and CVI Investments, Inc (0.30%). Company insiders that own EnteroMedics stock include Mark B Knudson and Peter M Delange.
Who sold EnteroMedics stock? Who is selling EnteroMedics stock?
EnteroMedics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
How do I buy EnteroMedics stock?
Shares of EnteroMedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of EnteroMedics stock cost?
One share of EnteroMedics stock can currently be purchased for approximately $5.84.
EnteroMedics (ETRM) Chart for Thursday, March, 23, 2017